Response to: ‘Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis’ by Wallace et al

We thank Dr Wallace et al for their response to our recently published article ‘Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis’, highlighting some methodological limitations of our study.1 2 One of the limitations mentioned by Wallace and colleagues is the inclusion of incident and prevalent cases and since only 15 out of 192...